Get the Stockscreener App
4.93
2.95%
-0.15
After Hours:
5.02
0.09
+1.83%
Uniqure N V stock is traded at $4.93, with a volume of 492.64K.
It is down -2.95% in the last 24 hours and down -15.73% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$5.08
Open:
$5.08
24h Volume:
492.64K
Relative Volume:
0.18
Market Cap:
$240.98M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-1.2513
EPS:
-3.94
Net Cash Flow:
$-153.08M
1W Performance:
-2.38%
1M Performance:
-15.73%
6M Performance:
-5.19%
1Y Performance:
-26.53%
1-Day Range:
$4.915
$5.2699
1-Week Range:
$4.73
$5.2699
52-Week Range:
$3.73
$11.35
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure (NASDAQ:QURE) Shares Cross Below Two Hundred Day Moving Average of $5.63 - MarketBeat
When (QURE) Moves Investors should Listen - Stock Traders Daily
FDA grants Orphan Drug status to uniQure's Fabry therapy By Investing.com - Investing.com Canada
UniQure rises on orphan drug status for genetic disorder gene therapy - XM
uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy - TipRanks
FDA grants Orphan Drug status to uniQure's Fabry therapy - Investing.com India
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewswire
FDA grants Orphan Drug status to uniQure's Fabry therapy By Investing.com - Investing.com UK
uniQure's (QURE) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
uniQure (NASDAQ:QURE) Given Overweight Rating at Cantor Fitzgerald - Defense World
How did uniQure N.V. (QURE) fare last session? - US Post News
Acadian Asset Management LLC Reduces Holdings in uniQure (NASDAQ:QURE) - MarketBeat
(QURE) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Acadian Asset Management LLC Has $2.30 Million Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago - Yahoo Finance
Brokerages Set uniQure (NASDAQ:QURE) Price Target at $18.60 - MarketBeat
uniQure (NASDAQ:QURE) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Institutional owners may take dramatic actions as uniQure N.V.'s (NASDAQ:QURE) recent 11% drop adds to one-year losses - Simply Wall St
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.
Trading (QURE) With Integrated Risk Controls - Stock Traders Daily
uniQure N.V.’s Banking’s 100-Day Moving Average at 5.76: Will the Stock Break Through? - The InvestChronicle
Assenagon Asset Management S.A. Makes New Investment in uniQure (NASDAQ:QURE) - MarketBeat
uniQure Forecasted to Post FY2024 Earnings of ($4.84) Per Share (NASDAQ:QURE) - MarketBeat
FY2024 Earnings Forecast for uniQure Issued By HC Wainwright (NASDAQ:QURE) - Defense World
uniQure retains PT with Buy rating on gene therapy prospects - Investing.com
HC Wainwright Reaffirms "Buy" Rating for uniQure (NASDAQ:QURE) - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE) - Defense World
Is uniQure N.V. (QURE) worth investing in despite its undervalued state? - US Post News
QURE (uniQure NV) Cash From Other Investing Activities : $-366.44 Mil (TTM As of Jun. 2024) - GuruFocus.com
QURE (uniQure NV) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
uniQure NV (STU:UQ1) 3-Year EPS without NRI Growth Rate : -36.20% (As of Jun. 2024) - GuruFocus.com
QURE (uniQure NV) Change In Receivables : $90.64 Mil (TTM As of Jun. 2024) - GuruFocus.com
Vanguard Group Inc. Raises Position in uniQure (NASDAQ:QURE) - MarketBeat
Vanguard Group Inc. Acquires 109,740 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Short Interest Up 20.1% in July - MarketBeat
uniQure NV (STU:UQ1) Inventory-to-Revenue : 0.68 (As of Jun. 2024) - GuruFocus.com
uniQure NV (STU:UQ1) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment - TipRanks
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - StockTitan
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - Yahoo Finance
Analysts Set uniQure (NASDAQ:QURE) Price Target at $18.60 - MarketBeat
uniQure (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Implied Volatility Surging for uniQure (QURE) Stock Options - Yahoo Singapore News
Cantor Fitzgerald Weighs in on uniQure's FY2024 Earnings (NASDAQ:QURE) - MarketBeat
uniQure (NASDAQ:QURE) Expected to Earn FY2024 Earnings of ($3.14) Per Share - Defense World
StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell” - Defense World
How to Take Advantage of moves in (QURE) - Stock Traders Daily
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity (QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Upgraded to "Sell" by StockNews.com - MarketBeat
Leerink Partnrs Comments on uniQure's Q3 2025 Earnings (NASDAQ:QURE) - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):